New drug-eluting stents an overview on biodegradable and polymer-free next-generation stent systems

Circulation: Cardiovascular Interventions

Volumn 3, Issue 4, 2010, Pages 384-393

  Abizaid, Alexandre ^a   Costa Jr , J Ribamar ^a  

^a INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMAZONIA PAX; BIOFREEDOM; BIOLIMUS; BIOMATRIX; CARDIOMIND 0.014 INCHES SPARROW; CYPHER; ELIXIR DES PROGRAM; JACTAX; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYOLIMUS; NEVO; NOVOLIMUS; OPTIMA; PACLITAXEL; POLYMER; RAPAMYCIN; SIROLIMUS+EPC CAPTURE; SUPRALIMUS; SUPRALIMUS CORE; TACROLIMUS; UNCLASSIFIED DRUG; VESTASYNC; YUKON CHOICEDES;

ARTERY INTIMA PROLIFERATION; ARTICLE; BIODEGRADABILITY; CARDIAC PATIENT; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CORONARY STENT; DRUG EFFICACY; DRUG ELUTING STENT; HUMAN; IN-STENT RESTENOSIS; OPTICAL COHERENCE TOMOGRAPHY; PATIENT SAFETY; PRIORITY JOURNAL; STENT THROMBOSIS;

ANGIOPLASTY; ANIMALS; CLINICAL TRIALS AS TOPIC; COATED MATERIALS, BIOCOMPATIBLE; CONSTRICTION, PATHOLOGIC; DRUG-ELUTING STENTS; ENDOTHELIUM, VASCULAR; HUMANS; LACTIC ACID; METALS; POLYMERS; POSTOPERATIVE COMPLICATIONS; SIROLIMUS;

EID: 78650162093     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.109.891192     Document Type: Article

References (24)

1. Bertrand OF, Sipehia R, Mongrain R, Rodes J, Tardif JC, Bilodeau L, Cote G, Bourassa MG. Biocompatibility aspects of new stent technology. J Am Coll Cardiol. 1998;32:562-571. (Pubitemid 28435237)
2. Nakazawa G, Finn AV, Ladich E, Ribichini F, Coleman L, Kolodgie FD, Virmani R. Drug-eluting stent safety: Findings from preclinical studies. Expert Rev Cardiovasc Ther. 2008;6:1379-1391.
3. Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, Gold HK, Burke AP, Kolodgie FD, Virmani R. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: An autopsy study. Circulation. 2008;118:1138-1145.
4. Virmani R, Farb A, Guagliumi G, Kolodgie FD. Drug-eluting stents: Caution and concerns for long-term outcome. Coron Artery Dis. 2004;15: 313-318. (Pubitemid 39299245)
5. Hezi-Yamit A, SulliVan C, Wong J, David L, Chen M, Cheng P, Shumaker D, Wilcox JN, Udipi K. Impact of polymer hydrophilicity on biocompatibility: Implication for DES polymer design. J Biomed Mater Res A. 2009;90:133-141.
6. Feres F, Costa JR Jr, Abizaid A. Very late thrombosis after drug-eluting stents. Catheter Cardiovasc Interv. 2006;68:83-88. (Pubitemid 44024467)
7. Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, Vogel R, Hess O, Meier B, Windecker S. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation. 2007;115:2426-434. (Pubitemid 46717965)
8. Siqueira DA, Abizaid AA, Costa Jde R, Feres F, Mattos LA, Staico R, Abizaid AA, Tanajura LF, Chaves A, Centemero M, Sousa AG, Sousa JE. Late incomplete apposition after drug-eluting stent implantation: Incidence and potential for adverse clinical outcomes. Eur Heart J. 2007;28:1304-1309. (Pubitemid 47355986)
9. Kounis NG, Hahalis G, Theoharides TC. Coronary stents, hypersensitivity reactions, and the Kounis syndrome. J Interv Cardiol. 2007;20: 314-323. (Pubitemid 47429146)
10. Pendyala LK, Li J, Shinke T, Geva S, Yin X, Chen JP, King SB III, Robinson KA, Chronos NA, Hou D. Endothelium-dependent vasomotor dysfunction in pig coronary arteries with Paclitaxel-eluting stents is associated with inflammation and oxidative stress. J Am Coll Cardiol Cardiovasc Interv. 2009;2:253-262.
11. Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R. Drug-eluting stent and coronary thrombosis: Biological mechanisms and clinical implications. Circulation. 2007;115:1051-1058. (Pubitemid 46328299)
12. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R. Vascular responses to drug eluting stents: Importance of delayed healing. Arterioscler Thromb Vasc Biol. 2007;27:1500-1510. (Pubitemid 46986103)
13. Silva GV, Fernandes MR, Madonna R, Clubb F, Oliveira E, Jimenez- Quevedo P, Branco R, Lopez J, Angeli FS, Sanz-Ruiz R, Vaughn WK, Zheng Y, Baimbridge F, Canales J, Cardoso CO, Assad JA, Falotico R, Perin EC. Comparative healing response after sirolimus- and paclitaxel-eluting stent implantation in a pig model of restenosis. Catheter Cardiovasc Interv. 2009;73:801-808.
14. Hossainy S, Prabhu S. A mathematical model for predicting drug release from a biodurable drug-eluting stent coating. J Biomed Mater Res A. 2008;87:487-493.
15. Costa RA, Lansky AJ, Abizaid A, Müeller R, Tsuchiya Y, Mori K, Cristea E, Leon MB, Sousa JE, Schmidt T, Hauptmann KE, Grube E. Angiographic results of the first human experience with the Biolimus A9 drug-eluting stent for de novo coronary lesions. Am J Cardiol. 2006;98: 443-446. (Pubitemid 44177576)
16. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Davies S, Van Geuns RJ, Eerdmans P, Van Es GA, Meier B, Jüni P. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): A randomised non-inferiority trial. Lancet. 2008;372: 1163-1173.
17. Yamasaki M, Ako J, Honda Y, Hassan A, Koo B, Abizaid A, Fitzgerald P, Whitbourn R. Novel guidewire-based stent delivery system: Examination by intravascular ultrasound. Catheter Cardiovasc Interv. 2008;72: 47-51. (Pubitemid 352008981)
18. Koo BK, Yamasaki M, Ako J, Waseda K, Honda Y, Fitzgerald PJ, Abizaid A, Whitbourn RJ. Intravascular ultrasound analysis of smallvessel lesions treated with novel ultra-low profile, guidewire-based selfexpanding stent system. J Invasive Cardiol. 2008;20:647-650.
19. Dani S, Kukreja N, Parikh P, Joshi H, Prajapati J, Jain S, Thanvi S, Shah B, Dutta JP. Biodegradable-polymer-based, sirolimus-eluting Supralimus stent: 6-month angiographic and 30-month clinical follow-up results from the series I prospective study. EuroIntervention. 2008;4:59-63.
20. Costa JR Jr, Abizaid A, Costa R, Feres F, Tanajura LF, Abizaid A, Mattos LA, Staico R, Siqueira D, Sousa AG, Bonan R, Sousa JE. Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system. J Am Coll Cardiol Cardiovasc Interv. 2008;1:545-551.
21. Costa JR Jr, Abizaid A, Costa R, Feres F, Tanajura LF, Abizaid A, Maldonado G, Staico R, Siqueira D, Sousa AG, Bonan R, Sousa JE. 1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: The VESTASYNC I trial. J Am Coll Cardiol Cardiovasc Interv. 2009;2:422-427.
22. Byrne RA, Mehilli J, Iijima R, Schulz S, Pache J, Seyfarth M, Schömig A, Kastrati A. A polymer-free dual drug-eluting stent in patients with coronary artery disease: A randomized trial vs. polymer-based drugeluting stents. Eur Heart J. 2009;30:923-931.
23. Byrne RA, Iijima R, Mehilli J, Pinieck S, Bruskina O, Schömig A, Kastrati A. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. J Am Coll Cardiol Cardiovasc Interv. 2009;2:291-299.
24. Moore P, Barlis P, Spiro J, Ghimire G, Roughton M, Di Mario C, Wallis W, Ilsley C, Mitchell A, Mason M, Kharbanda R, Vincent P, Sherwin S, Dalby M. A randomized optical coherence tomography study of coronary stent strut coverage and luminal protrusion with rapamycin-eluting stents. J Am Coll Cardiol Cardiovasc Interv. 2009;2:437-444.